Bessemer Group Inc. bought a new position in InMode Ltd. (NASDAQ:INMD - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 34,800 shares of the healthcare company's stock, valued at approximately $617,000. Bessemer Group Inc. owned 0.05% of InMode at the end of the most recent quarter.
Other large investors have also made changes to their positions in the company. Raymond James Financial Inc. purchased a new position in shares of InMode in the 4th quarter worth $1,332,000. Handelsbanken Fonder AB raised its position in InMode by 34.3% in the first quarter. Handelsbanken Fonder AB now owns 36,400 shares of the healthcare company's stock valued at $646,000 after purchasing an additional 9,300 shares during the period. GAMMA Investing LLC raised its position in InMode by 13,923.8% in the first quarter. GAMMA Investing LLC now owns 2,945 shares of the healthcare company's stock valued at $520,000 after purchasing an additional 2,924 shares during the period. Townsquare Capital LLC raised its position in InMode by 43.2% in the fourth quarter. Townsquare Capital LLC now owns 17,029 shares of the healthcare company's stock valued at $284,000 after purchasing an additional 5,137 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in InMode by 16.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 146,709 shares of the healthcare company's stock valued at $2,450,000 after purchasing an additional 21,229 shares during the period. 68.04% of the stock is owned by hedge funds and other institutional investors.
InMode Stock Performance
Shares of INMD stock traded down $0.06 on Friday, reaching $15.16. 595,953 shares of the company's stock traded hands, compared to its average volume of 1,226,497. InMode Ltd. has a 12-month low of $13.14 and a 12-month high of $19.85. The company has a market capitalization of $957.95 million, a P/E ratio of 6.50 and a beta of 1.95. The business's 50 day moving average price is $14.33 and its two-hundred day moving average price is $16.28.
InMode (NASDAQ:INMD - Get Free Report) last issued its earnings results on Monday, April 28th. The healthcare company reported $0.31 EPS for the quarter, missing analysts' consensus estimates of $0.45 by ($0.14). The firm had revenue of $77.87 million during the quarter, compared to analysts' expectations of $82.21 million. InMode had a net margin of 44.79% and a return on equity of 17.17%. The business's revenue for the quarter was down 3.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.32 EPS. Research analysts predict that InMode Ltd. will post 1.75 earnings per share for the current year.
Analysts Set New Price Targets
Several research analysts have commented on INMD shares. Barclays cut their price objective on InMode from $29.00 to $24.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 30th. Canaccord Genuity Group cut their price objective on InMode from $17.00 to $15.00 and set a "hold" rating on the stock in a research report on Tuesday, April 29th. BTIG Research lowered InMode from a "buy" rating to a "neutral" rating in a research report on Tuesday, April 29th. Needham & Company LLC reiterated a "hold" rating on shares of InMode in a research note on Monday, April 28th. Finally, UBS Group cut their price target on InMode from $19.00 to $16.25 and set a "neutral" rating on the stock in a research note on Tuesday, April 29th. Seven analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat.com, InMode has a consensus rating of "Hold" and a consensus price target of $18.54.
Get Our Latest Report on INMD
InMode Profile
(
Free Report)
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
Featured Articles
Before you consider InMode, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InMode wasn't on the list.
While InMode currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
